**Introduction:**
- Anti-platelet therapy including aspirin (ASA) and clopidogrel is recognized as clinically important in patients at risk of developing thrombotic events.
- Recently it has been realized that empiric therapeutic dosing is suboptimal due to inter-patient variability with regard to response, receptor concentration etc.
- Hence there is a clinical need to monitor such therapies on an individual basis.
- Traditional platelet tests including light transmission aggregometry (LTA) are inconvenient for acute diagnostic testing. Hence, the introduction of “near- patient” test systems.
- Here we describe the utility of a point-of-care (POC) test platform (PlateletWorks®) for monitoring platelet response to ADP and arachidonic acid (AA) as the agonists.

**Methods & Procedure:**
PlateletWorks (Helena Laboratories, Beaumont, TX) evaluates non-anticoagulated whole blood as the sample medium. It utilizes the principle of differential platelet counting in either the absence or presence of a platelet agonist (ADP, collagen, AA etc.) as a direct indication of platelet function. Results may be expressed as either % aggregation or % inhibition.

In human clinical trials subjects (n=205) were evaluated for their response to ADP (20μM) and a second group of subjects (n=40) were evaluated for their response to AA (either 5μM or 1.25mg) on both the Plateletworks and LTA (Chronolog, Haverstown, PA) test platforms.

**Results:**
The comparative data for each agonist between the two platforms are shown in Figures 1 & 2. The correlation between the two systems for ADP was r=0.91. For AA, as LTA provides a qualitative and Plateletworks a quantitative measure of response data were analyzed using McNemar test of symmetry with a calculated Cohen’s kappa value of 61.5%.

**Conclusions:**
- This novel POC test for platelet response may be a suitable peri-procedural screening assay to determine the effective dose of administered pharmaceutical on an individual patient basis.
- It may also provide clinical decision as to alternative anti-platelet therapies.
- Large scale studies both in vascular disease and other disease processes are ongoing.

**Agonists:** ADP - FDA approved (’91); AA - currently under FDA review.

---

**Figure 1:** Linear regression for ADP between two systems

\[ y = 0.8753x + 17.656 \]
\[ R = 0.91 \]

**Figure 2:** Statistical analysis of laboratory methods

- Statistical analysis: Agreement 90.8%
- Positive agreement: 75.0%
- Negative agreement: 90.0%
- Cohen’s kappa: 61.5% (>75% indicates high agreement)